The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

• Status: Terminated
• Trial end date: 2019-08-21
• Target enrollment: 0
• Participant gender: All

Summary

The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Collaborator: Avid Radiopharmaceuticals

Criteria

Inclusion Criteria:

1. Patients with extra-cardiac biopsy-proven AL or ATTR amyloidosis

2. Patients with a ratio of affected to unaffected free light chains >5 or free light chain difference of >50

Exclusion Criteria:

1. Echocardiographic evidence of cardiac amyloidosis with septal and posterior wall thickness ≥ 13mm

2. Contraindication to florbetapir or its components

3. Refusal to participate in the study